4DMT's gene therapy reduced need for standard-of-care injections to treat age-associated vision loss

4D Molecular Therapeutics’ one-time gene therapy reduced the need for annual injections in patients with age-related blindness in a mid-stage trial.

The company on Wednesday …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

4DMT's gene ther­a­py re­duced need for stan­dard-of-care in­jec­tions to treat age-as­so­ci­at­ed vi­sion loss